mProX™ Human EGFR Stable Cell Line

Product Information

Target Protein

EGFR

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research; Inflammation Research

Related Diseases

Inflammatory Skin And Bowel Disease; Lung Cancer

Gene ID

1956

UniProt ID

P00533

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

A transmembrane protein called the epidermal growth factor receptor (EGFR) binds to extracellular protein ligands that are members of the epidermal growth factor family (EGF family). The ErbB family of receptors, which consists of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3), and Her 4 (ErbB-4), includes the epidermal growth factor receptor. Mutations altering EGFR expression or activity have the potential to cause cancer in a variety of cancer types. In humans, over-expression of EGFR and other receptor tyrosine kinases is linked to the development of a wide range of malignancies, while deficient signaling is linked to disorders like Alzheimer's. The customized EGFR stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat David

Recommended for all labs based on my experience of using this EGFR cell line. May 23 2021

chat Verified Customer

chat Ashley

The EGFR KO cell line was an indispensable tool in my research. The cell line's stability and reproducibility were outstanding, allowing for reliable results across multiple experiments. Sep 03 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 EGFR and HER2 expression in colorectal cancer cell lines and their correlation with sensitivity to gefitinib.

On the left, cells were exposed to escalating dosages of gefitinib for a duration of 72 hours. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test was utilized to ascertain the vitality of the cells. Right, IC50 values for gefitinib were evaluated and linked with EGFR and HER2 total and phosphorylated levels in LoVo cells (30 μg) and A431 cell line (1 μg).

Ref: Van Schaeybroeck, Sandra, et al. "Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy." Clinical cancer research 11.20 (2005): 7480-7489.

Pubmed: 16243822

DOI: 10.1158/1078-0432.CCR-05-0328

Research Highlights

Patients with lung cancer with the EGFR T790M mutation who had experienced disease progression following previous EGFR tyrosine kinase inhibitor therapy showed a significant level of activity with AZD9291.
Jänne, Pasi A., et al. "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer." New England Journal of Medicine 372.18 (2015): 1689-1699.
Pubmed: 25923549 DOI: 10.1056/NEJMoa1411817

With a similar safety profile and a lower incidence of major side events, osimertinib demonstrated efficacy in the first-line therapy of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) that was superior to that of typical EGFR-TKIs.
Soria, Jean-Charles, et al. "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer." New England journal of medicine 378.2 (2018): 113-125.
Pubmed: 29151359 DOI: 10.1056/NEJMoa1713137